Referral of intravenous drug users for antiviral treatment: Effectiveness of hepatitis C case-finding programmes

Central European Journal of Public Health

Volumn 20, Issue 3, 2012, Pages 223-225

  Gazdag, Gábor ^a   Horváth, Gergely ^b   Szabó, Olga ^a   Ungvari, Gabor S ^c  

^a Szent Istvan and Szent Laszlo Hospitals   (Hungary)

^b National Institute of Epidemiology   (Hungary)

^c UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

Hepatitis C; Intravenous drug users; Screening programme

Indexed keywords

EID: 84870793129     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: 10.21101/cejph.a3747     Document Type: Article

References (18)

1. Quaglio GL, Lugoboni F, Pajusco B, Sarti M, Talamini G, Mezzelani P, et al.; GICS. Hepatitis C virus infection: prevalence, predictor variables and prevention opportunities among drug users in Italy. J Viral Hepat. 2003 Sep; 10(5):394-400. (Pubitemid 37159426)
2. Gerlich M, Gschwend P, Uchtenhagen A, Kramer A, Rehm J. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol. 2006;21(7):545-9. (Pubitemid 44578332)
3. Lidman C, Norden L, Kaberg M, Käll K, Franck J, Aleman S, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis. 2009;41(9):679-84.
4. Erratum in: Scand J Infect Dis. 2009;41(9):684.
5. Kolarić B, Stajduhar D, Gajnik D, Rukavina T, Wiessing L. Seroprevalence of blood-borne infections and population sizes estimates in a population of injecting drug users in Croatia. Cent Eur J Public Health. 2010 Jun; 18(2):104-9.
6. Merkinaite S, Lazarus JV, Gore C. Addressing HCV infection in Europe: reported, estimated and undiagnosed cases. Cent Eur J Public Health. 2008 Sep; 16(3):106-10.
7. Gerevich J. Issues in the outpatient treatment of drug addict patients. In: Németh A, Gerevich J, editors. Addictions. Budapest: Medicina; 2000. p. 52-72. (In Hungarian.)
8. Osztrogonácz H, Gerevich J, Horváth G, Tolvaj G, Dávid K. Prevalence of chronic viral hepatitis in drug abusers. Orv Hetil. 2000 Apr. 2;141(14):715-8. (In Hungarian.)
9. Csohan Á, Csorba J, Keller É, Zacher G. Health aspects and consequences of drug abuse. In: Nyírády A, Felvinczi K, editors. Report about the Hungarian drug situation. Budapest: ICSSZEM Professional series; 2004. p. 81-9. (In Hungarian).
10. Takacs IG. Tendencies of HIV and hepatitis prevalence in intravenous drug users. In: Felvinczy K, Nyírády A, editors. Drug policy in numbers. Budapest: L'Harmattan; 2009. p. 265-8. (In Hungarian.)
11. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003 Feb; 37(2):443-51. (Pubitemid 36152544)
12. Protocol of the Ministry of Health for the antiviral treatment of the chronic viral hepatitis [Internet]. [cited 2009 Nov. 14]. Available from: http://www.eum.hu/egeszsegpolitika/minosegfejlesztes/gasztro-hepatitis.
13. Hungarian Drug Focal Point. 2009 report on the drug use in Hungary for EMCDDA. Budapest: NFP; 2009. (In Hungarian.)
14. Takács IG. Harm reduction in numbers. In: Felvinczy K, Nyírády A, editors. Drug policy in numbers. Budapest: L'Harmattan; 2009. p. 233-78. (In Hungarian.)
15. Anderson EM, Mandeville RP, Hutchinson SJ, Cameron SO, Mills PR, Fox R, et al. Evaluation of a general practice based hepatitis C virus screening intervention. Scott Med J. 2009 Aug; 54(3):3-7.
16. Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess. 2006 Sep; 10(32):iii-iv, ix-xii, 1-93.
17. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM. 2001 Mar; 94(3):153-8. (Pubitemid 32242003)
18. Serfaty MA, Lawrie A, Smith B, Brind AM, Watson JP, Gilvarry E, et al. Risk factors and medical follow-up of drug users tested for hepatitis C - can the risk of transmission be reduced? Drug Alcohol Rev. 1997 Dec; 16(4):339-47. (Pubitemid 127532660)